Skip to main content

COVID-19 treatment: Roche Products Pty Ltd, casirivimab + imdevimab (RONAPREVE)

On 15 October 2021 the TGA granted provisional approval to Roche Products Pty Ltd for its COVID-19 treatment - casirivimab + imdevimab (RONAPREVE) - making it the third COVID-19 treatment to receive regulatory approval in Australia.

Last updated

Help us improve the Therapeutic Goods Administration site